Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • Our Story
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • 200.Cravath

Cravath’s London Office Moves to 100 Cheapside

Read More

People

Margaret T.
Segall

Partner, Litigation

msegall@cravath.com
  • New York+1-212-474-1231
    • E-mail
    • Twitter
    • Facebook
    • LinkedIn
  • PDF
  • Vcard
  • Overview
  • Credentials
  • Featured Work
  • News & Insights

Maggie Segall is a member of the Antitrust Practice. Her practice focuses on transactional matters, antitrust regulatory approval, and government investigations, including civil conduct investigations brought by both federal and state antitrust authorities, as well as general antitrust counseling and critical antitrust litigation. She has advised a wide variety of clients in diverse industries, including aerospace and aviation, pharmaceuticals, life sciences, consumer products, media, manufacturing and technology.

Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:

  • PepsiCo’s pending $1.95 billion acquisition of poppi;
  • Viatris’s divestitures totaling $6.94 billion in value, including the $3.335 billion combination of its biosimilars portfolio with Biocon Biologics and the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses;
  • Aon plc’s $13 billion acquisition of NFP;
  • Cisco’s $28 billion acquisition of Splunk;
  • Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals;
  • Deutsche Börse AG’s €3.9 billion recommended takeover offer for SimCorp A/S;
  • Altra Industrial’s $5 billion acquisition by Regal Rexnord;

  • RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;

  • ADT’s $1.2 billion equity investment from State Farm;

  • Micro Focus’s $6 billion acquisition by OpenText;

  • Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;

  • Afterpay Limited’s $29 billion acquisition by Block;
  • GW Pharmaceuticals plc’s $7.2 billion acquisition by Jazz Pharmaceuticals plc;
  • National Grid’s £7.8 billion acquisition of Western Power Distribution from PPL and the $3.8 billion sale of Narragansett Electric to PPL;
  • AerCap Holdings N.V.’s $30 billion acquisition of GE Capital Aviation Services and $5.4 billion acquisition of International Lease Finance Corporation;
  • DiaSorin S.p.A.’s $1.8 billion acquisition of Luminex Corporation;
  • Centrica plc’s $3.625 billion divestiture of its North American energy supply, services and trading business (Direct Energy) to NRG Energy;
  • Mylan N.V.’s $50 billion combination with Upjohn, a division of Pfizer, to form Viatris; its $9.9 billion acquisition of Meda; and its $5.6 billion acquisition of Abbott Laboratories’s non‑U.S. developed markets specialty and branded generics business;
  • Occidental Petroleum Corp.’s $57 billion acquisition of Anadarko Petroleum Corp.;
  • US Foods Holding Corp.’s $1.8 billion acquisition of five operating companies of Services Group of America;
  • Pinnacle Foods Inc.’s $10.9 billion acquisition by Conagra Brands, Inc.;
  • Time Warner Inc.’s $109 billion sale to AT&T;
  • DreamWorks Animation SKG, Inc.’s $4.1 billion sale to NBCUniversal, LLC, a division of Comcast Corporation;
  • Anheuser-Busch InBev’s $123 billion acquisition of SABMiller and the $12 billion sale of SABMiller’s U.S. and global Miller-branded businesses to Molson Coors;
  • Alere’s $8 billion acquisition by Abbott Laboratories;
  • H.J. Heinz Company’s $60 billion merger with Kraft Foods Group to create The Kraft Heinz Company;
  • Unilever’s acquisitions of Murad and Dermalogica and its $2.15 billion sale of its North America pasta sauces business under the Ragú and Bertolli brands to Mizkan Group;
  • Integrys Energy Group’s $9.1 billion acquisition by Wisconsin Energy Corporation;
  • InterMune’s $8.9 billion acquisition by Roche;
  • Grupo Modelo’s $20.1 billion acquisition by Anheuser-Busch InBev;
  • Zale Corporation’s $1.4 billion acquisition by Signet Jewelers; and
  • Life Technologies’s $15.8 billion sale to Thermo Fisher Scientific.

In addition, Ms. Segall regularly handles civil conduct investigations and complex antitrust litigation. Some of her recent and notable litigations include:

  • Representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
  • Representing Epic Systems, a large provider of health information technology, in an action filed by Particle Health asserting monopolization, among other claims, arising out of alleged conduct in an alleged market for “payer platforms.”
  • Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history. Ms. Segall was part of the team that secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
  • Represented Time Warner Inc. in winning the lawsuit filed by the Department of Justice (DOJ) seeking to block Time Warner’s $109 billion sale to AT&T, which culminated in a six‑week trial.

Ms. Segall was named “Dealmaker of the Year” by Global Competition Review (GCR) in 2025, and has been repeatedly recognized by Chambers USA and The Legal 500 US, including as a “Leading Lawyer” for antitrust merger control. She has been selected for Crain’s New York Business’s list of “Notable Women in Law,” and Lawdragon’s lists of “500 Leading Global Antitrust & Competition Lawyers” and “500 Leading Litigators in America.” In addition to her inclusion in Bloomberg Law’s and GCR’s “40 Under 40” lists, Benchmark Litigation included Ms. Segall on its “40 & Under List” and consistently recognized her as a “Future Star.”

Among other accolades, Who’s Who Legal has previously recommended Ms. Segall for her antitrust work, including naming her the “Most Highly Regarded Future Leader” in Competition in North America. Ms. Segall was also recognized for her antitrust work by LMG Life Sciences, and she has received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.” She was additionally recognized as one of Law360’s “Rising Stars” in Competition.

Ms. Segall is a Fellow of the American Bar Foundation and a member of the Antitrust Sections for the American Bar Association, New York State Bar Association and International Bar Association, where she also serves as a Publications Officer.

Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.

Ms. Segall joined Cravath in 2008 and was elected a partner in 2016. She currently serves as Litigation Hiring Partner and is a member of the Diversity Committee.

Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:

  • PepsiCo’s pending $1.95 billion acquisition of poppi;
  • Viatris’s divestitures totaling $6.94 billion in value, including the $3.335 billion combination of its biosimilars portfolio with Biocon Biologics and the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses;
  • Aon plc’s $13 billion acquisition of NFP;
  • Cisco’s $28 billion acquisition of Splunk;
  • Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals;
  • Deutsche Börse AG’s €3.9 billion recommended takeover offer for SimCorp A/S;
  • Altra Industrial’s $5 billion acquisition by Regal Rexnord;

  • RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;

  • ADT’s $1.2 billion equity investment from State Farm;

  • Micro Focus’s $6 billion acquisition by OpenText;

  • Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;

  • Afterpay Limited’s $29 billion acquisition by Block;
  • GW Pharmaceuticals plc’s $7.2 billion acquisition by Jazz Pharmaceuticals plc;
  • National Grid’s £7.8 billion acquisition of Western Power Distribution from PPL and the $3.8 billion sale of Narragansett Electric to PPL;
  • AerCap Holdings N.V.’s $30 billion acquisition of GE Capital Aviation Services and $5.4 billion acquisition of International Lease Finance Corporation;
  • DiaSorin S.p.A.’s $1.8 billion acquisition of Luminex Corporation;
  • Centrica plc’s $3.625 billion divestiture of its North American energy supply, services and trading business (Direct Energy) to NRG Energy;
  • Mylan N.V.’s $50 billion combination with Upjohn, a division of Pfizer, to form Viatris; its $9.9 billion acquisition of Meda; and its $5.6 billion acquisition of Abbott Laboratories’s non‑U.S. developed markets specialty and branded generics business;
  • Occidental Petroleum Corp.’s $57 billion acquisition of Anadarko Petroleum Corp.;
  • US Foods Holding Corp.’s $1.8 billion acquisition of five operating companies of Services Group of America;
  • Pinnacle Foods Inc.’s $10.9 billion acquisition by Conagra Brands, Inc.;
  • Time Warner Inc.’s $109 billion sale to AT&T;
  • DreamWorks Animation SKG, Inc.’s $4.1 billion sale to NBCUniversal, LLC, a division of Comcast Corporation;
  • Anheuser-Busch InBev’s $123 billion acquisition of SABMiller and the $12 billion sale of SABMiller’s U.S. and global Miller-branded businesses to Molson Coors;
  • Alere’s $8 billion acquisition by Abbott Laboratories;
  • H.J. Heinz Company’s $60 billion merger with Kraft Foods Group to create The Kraft Heinz Company;
  • Unilever’s acquisitions of Murad and Dermalogica and its $2.15 billion sale of its North America pasta sauces business under the Ragú and Bertolli brands to Mizkan Group;
  • Integrys Energy Group’s $9.1 billion acquisition by Wisconsin Energy Corporation;
  • InterMune’s $8.9 billion acquisition by Roche;
  • Grupo Modelo’s $20.1 billion acquisition by Anheuser-Busch InBev;
  • Zale Corporation’s $1.4 billion acquisition by Signet Jewelers; and
  • Life Technologies’s $15.8 billion sale to Thermo Fisher Scientific.

In addition, Ms. Segall regularly handles civil conduct investigations and complex antitrust litigation. Some of her recent and notable litigations include:

  • Representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
  • Representing Epic Systems, a large provider of health information technology, in an action filed by Particle Health asserting monopolization, among other claims, arising out of alleged conduct in an alleged market for “payer platforms.”
  • Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history. Ms. Segall was part of the team that secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
  • Represented Time Warner Inc. in winning the lawsuit filed by the Department of Justice (DOJ) seeking to block Time Warner’s $109 billion sale to AT&T, which culminated in a six‑week trial.

Ms. Segall was named “Dealmaker of the Year” by Global Competition Review (GCR) in 2025, and has been repeatedly recognized by Chambers USA and The Legal 500 US, including as a “Leading Lawyer” for antitrust merger control. She has been selected for Crain’s New York Business’s list of “Notable Women in Law,” and Lawdragon’s lists of “500 Leading Global Antitrust & Competition Lawyers” and “500 Leading Litigators in America.” In addition to her inclusion in Bloomberg Law’s and GCR’s “40 Under 40” lists, Benchmark Litigation included Ms. Segall on its “40 & Under List” and consistently recognized her as a “Future Star.”

Among other accolades, Who’s Who Legal has previously recommended Ms. Segall for her antitrust work, including naming her the “Most Highly Regarded Future Leader” in Competition in North America. Ms. Segall was also recognized for her antitrust work by LMG Life Sciences, and she has received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.” She was additionally recognized as one of Law360’s “Rising Stars” in Competition.

Ms. Segall is a Fellow of the American Bar Foundation and a member of the Antitrust Sections for the American Bar Association, New York State Bar Association and International Bar Association, where she also serves as a Publications Officer.

Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.

Ms. Segall joined Cravath in 2008 and was elected a partner in 2016. She currently serves as Litigation Hiring Partner and is a member of the Diversity Committee.

Education

  • J.D., 2008, Harvard Law School
    cum laude
  • A.B., 2003, Harvard College
    magna cum laude

Admitted In

  • New York

Professional Affiliations

American Bar Foundation

  • Fellow, since 2019

American Bar Association

International Bar Association

New York State Bar Association

Rankings

Benchmark Litigation

  • Future Star (2025-2019)
  • 40 & Under List (2022-2017)

Bloomberg Law

  • They’ve Got Next: The 40 Under 40 (2022)

Chambers USA

  • Antitrust - New York (2024-2019)

Crain’s New York Business

  • Notable Women in Law (2023)

Global Competition Review

  • “Dealmaker of the Year” (2025)
  • 40 Under 40 (2020)

Euromoney Legal Media Group

  • LMG Life Sciences Star – Antitrust (2024)

Law360

  • Rising Star: Competition Lawyers Under 40 to Watch (2018)

Lawdragon

  • 500 Leading Global Antitrust & Competition Lawyers (2025)
  • 500 Leading Litigators in America (2025, 2024, 2023)

The Legal 500 US

  • Antitrust (2024-2019)

Super Lawyers - New York

  • Antitrust Litigation (2021)
  • General Litigation – Rising Stars (2019‑2015)

Who’s Who Legal

  • Competition (2021-2017)
  • #1 Most Highly Regarded Future Leader in Competition - North America (2019)

Americas Rising Star Awards - Best in Antitrust/Competition, Euromoney Legal Media Group (2018)

Deals & Cases

March 17, 2025

PepsiCo’s $1.95 Billion Acquisition of poppi

On March 17, 2025, PepsiCo, Inc. (“PepsiCo”) announced that it has entered into a definitive agreement to acquire poppi, a prebiotic soda brand, for $1.95 billion, including $300 million of anticipated cash tax benefits for a net purchase price of $1.65 billion. The transaction also includes an additional potential earnout consideration subject to the achievement of certain performance milestones within a specified period after closing of the transaction. Cravath is representing PepsiCo in connection with the transaction.

Deals & Cases

January 29, 2025

Dowlais Group plc’s £1.16 Billion Recommended Cash and Share Combination with American Axle & Manufacturing Holdings, Inc.

On January 29, 2025, Dowlais Group plc (“Dowlais”), a specialist engineering group focused on the automotive sector, and American Axle & Manufacturing Holdings, Inc. (“AAM”), a leading automotive and mobility supplier, announced that their boards have reached agreement on the terms of a recommended cash and share combination. Under the terms of the combination, each Dowlais shareholder will be entitled to receive 0.0863 new AAM shares, 42 pence in cash and up to 2.8 pence in the form of dividends to be paid prior to completion. Dowlais shareholders will own approximately 49% of AAM upon closing. The offer values Dowlais at approximately £1.16 billion.

Deals & Cases

January 28, 2025

Paragon 28’s $1.2 Billion Acquisition by Zimmer Biomet

On January 28, 2025, Paragon 28, Inc. (“Paragon 28”), a leading medical device company focused on the foot and ankle orthopedic segment, and Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”), a global medical technology leader, announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of common stock of Paragon 28 for an upfront payment of $13.00 per share in cash, corresponding to an equity value of approximately $1.1 billion and an enterprise value of approximately $1.2 billion. Paragon 28 shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $1.00 per share in cash if certain revenue milestones are achieved. Cravath is representing Paragon 28 in connection with the transaction.

Deals & Cases

November 13, 2024

Just Eat Takeaway.com’s Sale of Grubhub to Wonder

On November 13, 2024, Just Eat Takeaway.com N.V. (“Just Eat Takeaway.com”), one of the world’s leading global online food delivery companies, announced that it has entered into a definitive agreement to sell Grubhub Inc. (“Grubhub”) to Wonder Group, Inc. (“Wonder”) for an enterprise value of $650 million. Grubhub will be transferred with its $500 million of senior notes. Cravath is representing Just Eat Takeaway.com in connection with the transaction.

Deals & Cases

October 07, 2024

Vista Outdoor’s $1.125 Billion Sale of Revelyst to SVP

On October 4, 2024, Vista Outdoor Inc. (“Vista Outdoor”), the parent company of more than three dozen renowned brands that design, manufacture and market sporting and outdoor products, announced it has entered into a definitive agreement with funds managed by Strategic Value Partners, LLC, and its affiliates (“SVP”), a global alternative investment firm with approximately $19 billion of assets under management, to sell Revelyst in an all‑cash transaction based on an enterprise value of $1.125 billion. In connection with the SVP Transaction, Vista Outdoor also entered into an amendment to the merger agreement with Czechoslovak Group a.s. (“CSG”) to acquire The Kinetic Group, increasing the purchase price for The Kinetic Group to $2.225 billion. Together, the CSG Transaction and the SVP Transaction represent an enterprise value of $3.35 billion for Vista Outdoor and will deliver an estimated $45 per share in cash to Vista Outdoor stockholders. Cravath is representing Vista Outdoor in connection with the transaction.

Activities

April 03, 2025

GCR Recognizes Maggie Segall as Dealmaker of the Year at Its 2025 Awards

On April 1, 2025, Global Competition Review (GCR) named Cravath partner Margaret T. Segall “Dealmaker of the Year” as part of its 2025 Awards ceremony in Washington, D.C., which honored “the world’s leading antitrust lawyers, economists and enforcers.” The Dealmaker of the Year award recognized Maggie as “a lawyer whose superior knowledge, practical judgement and negotiation skills in merger clearance matters in 2024 demonstrates that they are among the very best in the field.”

Activities

February 28, 2025

Cravath and Harvard Law School Host International Fellowship Event

On February 26, 2025, Cravath and Harvard Law School hosted a program to celebrate the work of the Cravath International Fellows, which was held in Cambridge, Massachusetts. Established in 2006 by Cravath partners who are Harvard Law School alumni, under the leadership of the late Robert D. Joffe, the Cravath International Fellowships program provides financial assistance, including travel and living expenses, to students pursuing academic projects during their Winter Term with an international, transnational or comparative law focus. Approximately 12 Cravath International Fellowships are awarded annually.

Activities

February 26, 2025

Law360 Names Cravath a 2024 “Competition Practice Group of the Year”

On February 20, 2025, Cravath was featured by Law360 as a “Competition Practice Group of the Year.” The profile highlighted the Firm’s representations across litigation and antitrust clearance, including a “trailblazing antitrust verdict” for Epic Games in its trial victory against Google and the Firm’s successful antitrust guidance of Cisco Systems in its $28 billion acquisition of Splunk and of Aon PLC in its $13 billion acquisition of NFP. The profile also recognized Cravath’s successful defense of Robinhood Markets Inc. in antitrust claims before the Eleventh Circuit and victories for Meta in putative class action and individual antitrust litigation resulting in the dismissal of all claims.

Publications

February 11, 2025

G.J. Ligelis Jr., Alyssa Caples, Chris Fargo and Maggie Segall Co‑Author U.S. Chapters of Chambers “Investing In… 2025” Guide

Cravath partners G.J. Ligelis Jr., Alyssa K. Caples, Christopher K. Fargo and Margaret T. Segall co‑authored the U.S. Law & Practice chapter of the fifth edition of Chambers “Investing In… 2025” Guide, which was published in January 2025. The guide, which is part of the publisher’s Global Practice Guides series, examines country‑specific legal issues that arise from foreign direct investment (“FDI”) and cross‑border transactions in the more than 30 jurisdictions covered. The U.S. Law & Practice chapter surveys the legal system and regulatory framework for FDI in the country, analyzing the economic climate, as well as considerations related to mergers and acquisitions, corporate governance, capital markets, antitrust, national security, tax, employment and intellectual property.

Activities

February 03, 2025

Noah Phillips, Maggie Segall and Andrew Finch Speak at GCR Live: Law Leaders Global 2025

Cravath partners Noah J. Phillips, Margaret T. Segall and Andrew C. Finch participated in the Global Competition Review Live: Law Leaders Global 2025 program, which was held from January 29‑31, 2025, in Miami, Florida. Noah and Maggie interviewed Rebekah Jurata, General Counsel at American Investment Council, in a fireside chat about how antitrust enforcers have approached private equity – and what to expect under the new Trump Administration. Andrew spoke on a panel entitled “Antitrust: Exchange of competitively sensitive information: how much should we care about sharing?,” during which panelists discussed the limits and framework of cooperation between competitors in light of the European Commission and the Competition and Markets Authority’s new guidance, the withdrawal by the U.S. DOJ of its information sharing guidance and changes in the enforcement landscape as it relates to the exchange of competitively sensitive information.

Maggie Segall is a member of the Antitrust Practice. Her practice focuses on transactional matters, antitrust regulatory approval, and government investigations, including civil conduct investigations brought by both federal and state antitrust authorities, as well as general antitrust counseling and critical antitrust litigation. She has advised a wide variety of clients in diverse industries, including aerospace and aviation, pharmaceuticals, life sciences, consumer products, media, manufacturing and technology.

Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:

  • PepsiCo’s pending $1.95 billion acquisition of poppi;
  • Viatris’s divestitures totaling $6.94 billion in value, including the $3.335 billion combination of its biosimilars portfolio with Biocon Biologics and the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses;
  • Aon plc’s $13 billion acquisition of NFP;
  • Cisco’s $28 billion acquisition of Splunk;
  • Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals;
  • Deutsche Börse AG’s €3.9 billion recommended takeover offer for SimCorp A/S;
  • Altra Industrial’s $5 billion acquisition by Regal Rexnord;

  • RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;

  • ADT’s $1.2 billion equity investment from State Farm;

  • Micro Focus’s $6 billion acquisition by OpenText;

  • Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;

  • Afterpay Limited’s $29 billion acquisition by Block;
  • GW Pharmaceuticals plc’s $7.2 billion acquisition by Jazz Pharmaceuticals plc;
  • National Grid’s £7.8 billion acquisition of Western Power Distribution from PPL and the $3.8 billion sale of Narragansett Electric to PPL;
  • AerCap Holdings N.V.’s $30 billion acquisition of GE Capital Aviation Services and $5.4 billion acquisition of International Lease Finance Corporation;
  • DiaSorin S.p.A.’s $1.8 billion acquisition of Luminex Corporation;
  • Centrica plc’s $3.625 billion divestiture of its North American energy supply, services and trading business (Direct Energy) to NRG Energy;
  • Mylan N.V.’s $50 billion combination with Upjohn, a division of Pfizer, to form Viatris; its $9.9 billion acquisition of Meda; and its $5.6 billion acquisition of Abbott Laboratories’s non‑U.S. developed markets specialty and branded generics business;
  • Occidental Petroleum Corp.’s $57 billion acquisition of Anadarko Petroleum Corp.;
  • US Foods Holding Corp.’s $1.8 billion acquisition of five operating companies of Services Group of America;
  • Pinnacle Foods Inc.’s $10.9 billion acquisition by Conagra Brands, Inc.;
  • Time Warner Inc.’s $109 billion sale to AT&T;
  • DreamWorks Animation SKG, Inc.’s $4.1 billion sale to NBCUniversal, LLC, a division of Comcast Corporation;
  • Anheuser-Busch InBev’s $123 billion acquisition of SABMiller and the $12 billion sale of SABMiller’s U.S. and global Miller-branded businesses to Molson Coors;
  • Alere’s $8 billion acquisition by Abbott Laboratories;
  • H.J. Heinz Company’s $60 billion merger with Kraft Foods Group to create The Kraft Heinz Company;
  • Unilever’s acquisitions of Murad and Dermalogica and its $2.15 billion sale of its North America pasta sauces business under the Ragú and Bertolli brands to Mizkan Group;
  • Integrys Energy Group’s $9.1 billion acquisition by Wisconsin Energy Corporation;
  • InterMune’s $8.9 billion acquisition by Roche;
  • Grupo Modelo’s $20.1 billion acquisition by Anheuser-Busch InBev;
  • Zale Corporation’s $1.4 billion acquisition by Signet Jewelers; and
  • Life Technologies’s $15.8 billion sale to Thermo Fisher Scientific.

In addition, Ms. Segall regularly handles civil conduct investigations and complex antitrust litigation. Some of her recent and notable litigations include:

  • Representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
  • Representing Epic Systems, a large provider of health information technology, in an action filed by Particle Health asserting monopolization, among other claims, arising out of alleged conduct in an alleged market for “payer platforms.”
  • Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history. Ms. Segall was part of the team that secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
  • Represented Time Warner Inc. in winning the lawsuit filed by the Department of Justice (DOJ) seeking to block Time Warner’s $109 billion sale to AT&T, which culminated in a six‑week trial.

Ms. Segall was named “Dealmaker of the Year” by Global Competition Review (GCR) in 2025, and has been repeatedly recognized by Chambers USA and The Legal 500 US, including as a “Leading Lawyer” for antitrust merger control. She has been selected for Crain’s New York Business’s list of “Notable Women in Law,” and Lawdragon’s lists of “500 Leading Global Antitrust & Competition Lawyers” and “500 Leading Litigators in America.” In addition to her inclusion in Bloomberg Law’s and GCR’s “40 Under 40” lists, Benchmark Litigation included Ms. Segall on its “40 & Under List” and consistently recognized her as a “Future Star.”

Among other accolades, Who’s Who Legal has previously recommended Ms. Segall for her antitrust work, including naming her the “Most Highly Regarded Future Leader” in Competition in North America. Ms. Segall was also recognized for her antitrust work by LMG Life Sciences, and she has received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.” She was additionally recognized as one of Law360’s “Rising Stars” in Competition.

Ms. Segall is a Fellow of the American Bar Foundation and a member of the Antitrust Sections for the American Bar Association, New York State Bar Association and International Bar Association, where she also serves as a Publications Officer.

Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.

Ms. Segall joined Cravath in 2008 and was elected a partner in 2016. She currently serves as Litigation Hiring Partner and is a member of the Diversity Committee.

Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:

  • PepsiCo’s pending $1.95 billion acquisition of poppi;
  • Viatris’s divestitures totaling $6.94 billion in value, including the $3.335 billion combination of its biosimilars portfolio with Biocon Biologics and the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses;
  • Aon plc’s $13 billion acquisition of NFP;
  • Cisco’s $28 billion acquisition of Splunk;
  • Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals;
  • Deutsche Börse AG’s €3.9 billion recommended takeover offer for SimCorp A/S;
  • Altra Industrial’s $5 billion acquisition by Regal Rexnord;

  • RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;

  • ADT’s $1.2 billion equity investment from State Farm;

  • Micro Focus’s $6 billion acquisition by OpenText;

  • Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;

  • Afterpay Limited’s $29 billion acquisition by Block;
  • GW Pharmaceuticals plc’s $7.2 billion acquisition by Jazz Pharmaceuticals plc;
  • National Grid’s £7.8 billion acquisition of Western Power Distribution from PPL and the $3.8 billion sale of Narragansett Electric to PPL;
  • AerCap Holdings N.V.’s $30 billion acquisition of GE Capital Aviation Services and $5.4 billion acquisition of International Lease Finance Corporation;
  • DiaSorin S.p.A.’s $1.8 billion acquisition of Luminex Corporation;
  • Centrica plc’s $3.625 billion divestiture of its North American energy supply, services and trading business (Direct Energy) to NRG Energy;
  • Mylan N.V.’s $50 billion combination with Upjohn, a division of Pfizer, to form Viatris; its $9.9 billion acquisition of Meda; and its $5.6 billion acquisition of Abbott Laboratories’s non‑U.S. developed markets specialty and branded generics business;
  • Occidental Petroleum Corp.’s $57 billion acquisition of Anadarko Petroleum Corp.;
  • US Foods Holding Corp.’s $1.8 billion acquisition of five operating companies of Services Group of America;
  • Pinnacle Foods Inc.’s $10.9 billion acquisition by Conagra Brands, Inc.;
  • Time Warner Inc.’s $109 billion sale to AT&T;
  • DreamWorks Animation SKG, Inc.’s $4.1 billion sale to NBCUniversal, LLC, a division of Comcast Corporation;
  • Anheuser-Busch InBev’s $123 billion acquisition of SABMiller and the $12 billion sale of SABMiller’s U.S. and global Miller-branded businesses to Molson Coors;
  • Alere’s $8 billion acquisition by Abbott Laboratories;
  • H.J. Heinz Company’s $60 billion merger with Kraft Foods Group to create The Kraft Heinz Company;
  • Unilever’s acquisitions of Murad and Dermalogica and its $2.15 billion sale of its North America pasta sauces business under the Ragú and Bertolli brands to Mizkan Group;
  • Integrys Energy Group’s $9.1 billion acquisition by Wisconsin Energy Corporation;
  • InterMune’s $8.9 billion acquisition by Roche;
  • Grupo Modelo’s $20.1 billion acquisition by Anheuser-Busch InBev;
  • Zale Corporation’s $1.4 billion acquisition by Signet Jewelers; and
  • Life Technologies’s $15.8 billion sale to Thermo Fisher Scientific.

In addition, Ms. Segall regularly handles civil conduct investigations and complex antitrust litigation. Some of her recent and notable litigations include:

  • Representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
  • Representing Epic Systems, a large provider of health information technology, in an action filed by Particle Health asserting monopolization, among other claims, arising out of alleged conduct in an alleged market for “payer platforms.”
  • Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history. Ms. Segall was part of the team that secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
  • Represented Time Warner Inc. in winning the lawsuit filed by the Department of Justice (DOJ) seeking to block Time Warner’s $109 billion sale to AT&T, which culminated in a six‑week trial.

Ms. Segall was named “Dealmaker of the Year” by Global Competition Review (GCR) in 2025, and has been repeatedly recognized by Chambers USA and The Legal 500 US, including as a “Leading Lawyer” for antitrust merger control. She has been selected for Crain’s New York Business’s list of “Notable Women in Law,” and Lawdragon’s lists of “500 Leading Global Antitrust & Competition Lawyers” and “500 Leading Litigators in America.” In addition to her inclusion in Bloomberg Law’s and GCR’s “40 Under 40” lists, Benchmark Litigation included Ms. Segall on its “40 & Under List” and consistently recognized her as a “Future Star.”

Among other accolades, Who’s Who Legal has previously recommended Ms. Segall for her antitrust work, including naming her the “Most Highly Regarded Future Leader” in Competition in North America. Ms. Segall was also recognized for her antitrust work by LMG Life Sciences, and she has received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.” She was additionally recognized as one of Law360’s “Rising Stars” in Competition.

Ms. Segall is a Fellow of the American Bar Foundation and a member of the Antitrust Sections for the American Bar Association, New York State Bar Association and International Bar Association, where she also serves as a Publications Officer.

Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.

Ms. Segall joined Cravath in 2008 and was elected a partner in 2016. She currently serves as Litigation Hiring Partner and is a member of the Diversity Committee.

Education

  • J.D., 2008, Harvard Law School
    cum laude
  • A.B., 2003, Harvard College
    magna cum laude

Admitted In

  • New York

Professional Affiliations

American Bar Foundation

  • Fellow, since 2019

American Bar Association

International Bar Association

New York State Bar Association

Rankings

Benchmark Litigation

  • Future Star (2025-2019)
  • 40 & Under List (2022-2017)

Bloomberg Law

  • They’ve Got Next: The 40 Under 40 (2022)

Chambers USA

  • Antitrust - New York (2024-2019)

Crain’s New York Business

  • Notable Women in Law (2023)

Global Competition Review

  • “Dealmaker of the Year” (2025)
  • 40 Under 40 (2020)

Euromoney Legal Media Group

  • LMG Life Sciences Star – Antitrust (2024)

Law360

  • Rising Star: Competition Lawyers Under 40 to Watch (2018)

Lawdragon

  • 500 Leading Global Antitrust & Competition Lawyers (2025)
  • 500 Leading Litigators in America (2025, 2024, 2023)

The Legal 500 US

  • Antitrust (2024-2019)

Super Lawyers - New York

  • Antitrust Litigation (2021)
  • General Litigation – Rising Stars (2019‑2015)

Who’s Who Legal

  • Competition (2021-2017)
  • #1 Most Highly Regarded Future Leader in Competition - North America (2019)

Americas Rising Star Awards - Best in Antitrust/Competition, Euromoney Legal Media Group (2018)

Deals & Cases

March 17, 2025

PepsiCo’s $1.95 Billion Acquisition of poppi

On March 17, 2025, PepsiCo, Inc. (“PepsiCo”) announced that it has entered into a definitive agreement to acquire poppi, a prebiotic soda brand, for $1.95 billion, including $300 million of anticipated cash tax benefits for a net purchase price of $1.65 billion. The transaction also includes an additional potential earnout consideration subject to the achievement of certain performance milestones within a specified period after closing of the transaction. Cravath is representing PepsiCo in connection with the transaction.

Deals & Cases

January 29, 2025

Dowlais Group plc’s £1.16 Billion Recommended Cash and Share Combination with American Axle & Manufacturing Holdings, Inc.

On January 29, 2025, Dowlais Group plc (“Dowlais”), a specialist engineering group focused on the automotive sector, and American Axle & Manufacturing Holdings, Inc. (“AAM”), a leading automotive and mobility supplier, announced that their boards have reached agreement on the terms of a recommended cash and share combination. Under the terms of the combination, each Dowlais shareholder will be entitled to receive 0.0863 new AAM shares, 42 pence in cash and up to 2.8 pence in the form of dividends to be paid prior to completion. Dowlais shareholders will own approximately 49% of AAM upon closing. The offer values Dowlais at approximately £1.16 billion.

Deals & Cases

January 28, 2025

Paragon 28’s $1.2 Billion Acquisition by Zimmer Biomet

On January 28, 2025, Paragon 28, Inc. (“Paragon 28”), a leading medical device company focused on the foot and ankle orthopedic segment, and Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”), a global medical technology leader, announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of common stock of Paragon 28 for an upfront payment of $13.00 per share in cash, corresponding to an equity value of approximately $1.1 billion and an enterprise value of approximately $1.2 billion. Paragon 28 shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $1.00 per share in cash if certain revenue milestones are achieved. Cravath is representing Paragon 28 in connection with the transaction.

Deals & Cases

November 13, 2024

Just Eat Takeaway.com’s Sale of Grubhub to Wonder

On November 13, 2024, Just Eat Takeaway.com N.V. (“Just Eat Takeaway.com”), one of the world’s leading global online food delivery companies, announced that it has entered into a definitive agreement to sell Grubhub Inc. (“Grubhub”) to Wonder Group, Inc. (“Wonder”) for an enterprise value of $650 million. Grubhub will be transferred with its $500 million of senior notes. Cravath is representing Just Eat Takeaway.com in connection with the transaction.

Deals & Cases

October 07, 2024

Vista Outdoor’s $1.125 Billion Sale of Revelyst to SVP

On October 4, 2024, Vista Outdoor Inc. (“Vista Outdoor”), the parent company of more than three dozen renowned brands that design, manufacture and market sporting and outdoor products, announced it has entered into a definitive agreement with funds managed by Strategic Value Partners, LLC, and its affiliates (“SVP”), a global alternative investment firm with approximately $19 billion of assets under management, to sell Revelyst in an all‑cash transaction based on an enterprise value of $1.125 billion. In connection with the SVP Transaction, Vista Outdoor also entered into an amendment to the merger agreement with Czechoslovak Group a.s. (“CSG”) to acquire The Kinetic Group, increasing the purchase price for The Kinetic Group to $2.225 billion. Together, the CSG Transaction and the SVP Transaction represent an enterprise value of $3.35 billion for Vista Outdoor and will deliver an estimated $45 per share in cash to Vista Outdoor stockholders. Cravath is representing Vista Outdoor in connection with the transaction.

Activities

April 03, 2025

GCR Recognizes Maggie Segall as Dealmaker of the Year at Its 2025 Awards

On April 1, 2025, Global Competition Review (GCR) named Cravath partner Margaret T. Segall “Dealmaker of the Year” as part of its 2025 Awards ceremony in Washington, D.C., which honored “the world’s leading antitrust lawyers, economists and enforcers.” The Dealmaker of the Year award recognized Maggie as “a lawyer whose superior knowledge, practical judgement and negotiation skills in merger clearance matters in 2024 demonstrates that they are among the very best in the field.”

Activities

February 28, 2025

Cravath and Harvard Law School Host International Fellowship Event

On February 26, 2025, Cravath and Harvard Law School hosted a program to celebrate the work of the Cravath International Fellows, which was held in Cambridge, Massachusetts. Established in 2006 by Cravath partners who are Harvard Law School alumni, under the leadership of the late Robert D. Joffe, the Cravath International Fellowships program provides financial assistance, including travel and living expenses, to students pursuing academic projects during their Winter Term with an international, transnational or comparative law focus. Approximately 12 Cravath International Fellowships are awarded annually.

Activities

February 26, 2025

Law360 Names Cravath a 2024 “Competition Practice Group of the Year”

On February 20, 2025, Cravath was featured by Law360 as a “Competition Practice Group of the Year.” The profile highlighted the Firm’s representations across litigation and antitrust clearance, including a “trailblazing antitrust verdict” for Epic Games in its trial victory against Google and the Firm’s successful antitrust guidance of Cisco Systems in its $28 billion acquisition of Splunk and of Aon PLC in its $13 billion acquisition of NFP. The profile also recognized Cravath’s successful defense of Robinhood Markets Inc. in antitrust claims before the Eleventh Circuit and victories for Meta in putative class action and individual antitrust litigation resulting in the dismissal of all claims.

Publications

February 11, 2025

G.J. Ligelis Jr., Alyssa Caples, Chris Fargo and Maggie Segall Co‑Author U.S. Chapters of Chambers “Investing In… 2025” Guide

Cravath partners G.J. Ligelis Jr., Alyssa K. Caples, Christopher K. Fargo and Margaret T. Segall co‑authored the U.S. Law & Practice chapter of the fifth edition of Chambers “Investing In… 2025” Guide, which was published in January 2025. The guide, which is part of the publisher’s Global Practice Guides series, examines country‑specific legal issues that arise from foreign direct investment (“FDI”) and cross‑border transactions in the more than 30 jurisdictions covered. The U.S. Law & Practice chapter surveys the legal system and regulatory framework for FDI in the country, analyzing the economic climate, as well as considerations related to mergers and acquisitions, corporate governance, capital markets, antitrust, national security, tax, employment and intellectual property.

Activities

February 03, 2025

Noah Phillips, Maggie Segall and Andrew Finch Speak at GCR Live: Law Leaders Global 2025

Cravath partners Noah J. Phillips, Margaret T. Segall and Andrew C. Finch participated in the Global Competition Review Live: Law Leaders Global 2025 program, which was held from January 29‑31, 2025, in Miami, Florida. Noah and Maggie interviewed Rebekah Jurata, General Counsel at American Investment Council, in a fireside chat about how antitrust enforcers have approached private equity – and what to expect under the new Trump Administration. Andrew spoke on a panel entitled “Antitrust: Exchange of competitively sensitive information: how much should we care about sharing?,” during which panelists discussed the limits and framework of cooperation between competitors in light of the European Commission and the Competition and Markets Authority’s new guidance, the withdrawal by the U.S. DOJ of its information sharing guidance and changes in the enforcement landscape as it relates to the exchange of competitively sensitive information.

Cravath Bicentennial

Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

Explore

Cravath, Swaine & Moore LLP Logo
  • CONTACT US
  • OUR STORY
  • ALUMNI PORTAL
  • DISCLAIMERS & NOTICES

Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.